Peter Handrinos advises boards of directors, management teams, and entrepreneurs on corporate and securities law matters, with an emphasis on mergers and acquisitions and financing transactions for life sciences and technology companies. Over his 25-year career, Mr. Handrinos has advised many of the most prominent pharmaceutical, biotechnology, and medical device companies in the healthcare industry. The Legal 500 US describes Mr. Handrinos as “one of the best life sciences lawyers in Boston.”
Mr. Handrinos is recognized internationally for his leadership in the life sciences industry. He was named as the Corporate Attorney of the Year by LMG Life Sciences in 2021. He has been recognized for over 15 years as a leader in Life Sciences and ranked in Life Sciences: Corporate/Commercial by Chambers Global and in Band 1 in Corporate/M&A: Capital Markets by Chambers USA, where he is described by clients as “extremely experienced” with “very valuable insights across critical financing and governance matters.” He has been repeatedly recognized as a Life Sciences Star by LMG Life Sciences and listed as a leader in mergers and acquisitions by Best Lawyers in America.
Mr. Handrinos has led more than 75 IPOs for life sciences and technology companies. He also regularly advises companies on mergers and acquisitions transactions. In addition, he handles private and public financing transactions for his clients. He has represented all of the major US investment banks as underwriter’s counsel.
Firm recognized by LMG Life Sciences for excellence in the life science legal space.
Major deals, high-profile cases, and local know-how earn recognition from Law360.
Chambers USA recognized the firm as a “powerhouse in the capital markets space.”